Umecrine Cognition is a developer of pharmaceutical products to treat cognitive neurological disorders.
Umecrine Cognition has raised $2.6M in total funding. The most recent round was Convertible Note. The last funding was announced in July 2025.
Umecrine Cognition's investors include Almi Invest, Michael J. Fox Foundation, Ribbskottet, Karolinska, Partnerinvest Norr.
Umecrine Cognition is headquartered in Solna, Sweden.
Umecrine Cognition is a developer of pharmaceutical products to treat cognitive neurological disorders.
Umecrine Cognition is at the Convertible Note stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Umecrine Cognition — Funding & Investors." VCBacked, July 14, 2025, https://www.vcbacked.co/company/umecrine-cognition. Accessed October 29, 2026.
VCBacked. (2025). Umecrine Cognition — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/umecrine-cognition
{{cite web |title=Umecrine Cognition — Funding & Investors |url=https://www.vcbacked.co/company/umecrine-cognition |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated